The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: A randomized controlled trial

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Dalby, Chris ^a   Polanowski, Tomasz ^b   Larsson, Thomas ^b   Borgström, Lars ^b   Edsbäcker, Staffan ^b   Harrison, Tim W ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; ANDROSTANE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUTICASONE, SALMETEROL DRUG COMBINATION; FORMOTEROL; SALBUTAMOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SPUTUM LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CLEARANCE; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG POTENTIATION; HOSPITALIZATION; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; SPUTUM; SWEDEN; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENGLAND; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; SEVERITY OF ILLNESS INDEX; SPUTUM; SWEDEN; YOUNG ADULT;

EID: 73949146929     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-104     Document Type: Article

References (38)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2007. , http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989
2. World Health Statistics. , http://www.who.int/whosis/whostat/2008/en/index.html
3. National Institute for Clinical Excellence. Chronicobstructive pulmonary disease (Clinical Guideline 12) 2004, London:National Institute for Clinical Excellence.
4. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919. 10.1183/09031936.03.00027003, 14680078.
5. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety ofbudesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81. 10.1183/09031936.03.00031402, 12570112.
6. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, . for the TORCH investigators Salmeterol andfluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337, for the TORCH investigators.
7. Calverley PM, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456. 10.1016/S0140-6736(03)12459-2, 12583942.
8. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001, 52:529-538. 10.1046/j.0306-5251.2001.01493.x, 2014609, 11736861.
9. Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: a review of the evidence. Respir Med 2007, 101:685-695. 10.1016/j.rmed.2006.10.009, 17125984.
10. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003, 25(Suppl C):C28-C41. 10.1016/S0149-2918(03)80304-1, 14642802.
11. Edsbacker S, Wollmer P, Selroos O, Borgstrom L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids?. Pulm Pharmacol Ther 2008, 21:247-258. 10.1016/j.pupt.2007.08.005, 17950641.
12. Yanai M, Hatazawa J, Ojima F, Sasaki H, Itoh M, Ido T. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998, 11:1342-1348. 10.1183/09031936.98.11061342, 9657577.
13. Harrison TW, Wisniewski A, Honur J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001, 56:186-191. 10.1136/thorax.56.3.186, 1758787, 11182010.
14. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003, 58:258-260. 10.1136/thorax.58.3.258, 1746593, 12612308.
15. Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 2004, 1:356-363. 10.1513/pats.200403-025MS, 16113458.
16. Grebski E, Peterson C, Medici TC. Effect of physical and chemical methods of homogenization on inflammatory mediators in sputum of asthma patients. Chest 2001, 119:1521-1525. 10.1378/chest.119.5.1521, 11348963.
17. Guidance for Industry. Bioanalytical method validation. , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf
18. Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, Woodcock A. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000, 356:556-561. 10.1016/S0140-6736(00)02581-2, 10950233.
19. Rogers DF. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 2005, 18:1-8. 10.1016/j.pupt.2004.08.001, 15607121.
20. Singh SD, Whale C, Houghton N, Daley-Yates P, Kirby SM, Woodcock AA. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in chronic obstructive pulmonary disease. Br J Clin Pharmacol 2003, 55:375-381. 10.1046/j.1365-2125.2003.01758.x, 1884235, 12680886.
21. Melloni B, Germouty J. [The influence of a new beta agonist: formoterol on mucociliary function]. Rev Mal Respir 1992, 9:503-507.
22. Piatti G, Ambrosetti U, Santus P, Allegra L. Effects of salmeterol on cilia and mucus in COPD and pneumonia patients. Pharmacol Res 2005, 51:165-168. 10.1016/j.phrs.2004.07.006, 15629263.
23. Lindberg S, Khan R, Runer T. The effects of formoterol, a long-acting beta 2-adrenoceptor agonist, on mucociliary activity. Eur J Pharmacol 1995, 285:275-280. 10.1016/0014-2999(95)00416-I, 8575514.
24. Salathe M. Effects of beta-agonists on airway epithelial cells. J Allergy Clin Immunol 2002, 110:S275-S281. 10.1067/mai.2002.129412, 12464936.
25. Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996, 154:1868-1902.
26. Mortimer KJ, Tattersfield AE, Tang Y, Wu K, Lewis S, Hochhaus G, Harrison TW. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol 2007, 64:439-444. 10.1111/j.1365-2125.2007.02856.x, 2048552, 17711540.
27. Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, Centanni S. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004, 17:121-125. 10.1016/j.pupt.2004.01.001, 15123220.
28. Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv 2008, 21:77-84. 10.1089/jamp.2007.0643, 18518834.
29. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. Am J Respir Crit Care Med 2003, 168:779-782. 10.1164/rccm.200302-200OC, 12893646.
30. Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc 2004, 1:269-274. 10.1513/pats.200402-007MS, 16113445.
31. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006, 28:1042-1050. 10.1183/09031936.00074905, 17074919.
32. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001, 14(Suppl 1):S19-S26. 10.1089/08942680150506303, 11424889.
33. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998, 11:1111-1115. 10.1183/09031936.98.11051111, 9648964.
34. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102:1099-1108. 10.1016/j.rmed.2008.04.019, 18614347.
35. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:144-149. 10.1164/rccm.200602-244OC, 17053207.
36. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26. 10.1164/rccm.200707-973OC, 17916806.
37. Bennett WD, Almond MA, Zeman KL, Johnson JG, Donohue JF. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulmonary Pharmacology & Therapeutics 2006, 19:96-100. 10.1016/j.pupt.2005.04.001, 15970448.
38. Hasani A, Toms N, Agnew JE, Lloyd J, Dilworth JP. Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists. Respir Med 2005, 99:145-151. 10.1016/j.rmed.2004.07.004, 15715181.